Inventor

CLAUSEN HENRIK

DK62 patents

⚠️ This page may combine multiple inventors who share the name “CLAUSEN HENRIK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CLAUSEN HENRIK

BIOMEMBRANE INST

ABO genotyping

Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates

Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides

Synthesis of Lex ; dimeric Lex (difucosyl Y2 ; III3 FucV3 FucnLc6 Cer); sialylated forms thereof; and analogues thereof

Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates

Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates

Purified histo-blood group a glycosyltransferase and antibodies thereto

A-associated H-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing

Blood treatment method

A-associated H-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing

GLYCOZYM APS

Glycosylation using GalNac-T4 transferase

UDP-N-acetylglucosamine: galactose-β1, 3-N-acetylgalactosamine-α-R/(GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2GnT3

UDP-galactose: β-D-galactose-R 4-α-D-galac-tosyltransferase, α4Gal-T1

UDP-galactose: β-N-acetyl-glucosamine β-1,4-galactosyltransferase, β4Gal-T2

UDP-galactose: β-N-acetyl-glucosamine β-1,4-galactosyltransferase, β4Gal-T2

UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R / (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2GnT3

UDP-galactose: β-D-galactose-R 4-α-D-galactosyltransferase, α4Gal-T1

UDP-galactose: β-N-acetyl-glucosamine β1,3 galactosyltransferases, β3gal-T5

VELICO MEDICAL INC

Apparatus for prolonging survival of platelets

Methods for prolonging survival of platelets using UDP-galactose

Method of preparing non-human tissues for xenotransplantation using α-galactosidase

Streptomyces griseoplanus α-galactosidases for removing immunodominant α-galactose monosaccharides from blood group B or AB reactive cells

Compositions and methods for modifying blood cell carbohydrates

Methods of preparing tissues for xenotransplantation using alpha-galactosidases

UNIV COPENHAGEN

Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies

Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid

Lysosomal enzymes modified by cell based glycoengineering

Production of N-glycoproteins for enzyme assisted glycomodification

CLAUSEN HENRIK

Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies

Streptomyces griseoplanus comprising an α-galactosidase for removing immunodominant α-galactose monosaccharides from blood group B or AB reactive cells

β1,4mannosyltransferases

GO THERAPEUTICS INC

Tn-MUC4 binding polypeptides and uses thereof

Tn-MUC4 binding polypeptides and uses thereof

CORE3-MUC1 binding polypeptides and uses thereof

(unassigned)

UDP-N-acetyl-α-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase, gAlnAc-T3

UDP-galactose: β-N-acetyl-glucosamine β1,3galactosyltransferases, β3Gal-T5

DEFREES SHAWN

Glycopegylated interferon α

Glycopegylated granulocyte colony stimulating factor

KØBENHAVNS UNI

Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies

Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies

NEOSE TECHNOLOGIES INC

O-linked glycosylation of peptides

NOVO NORDISK AS

Compositions and methods for the preparation of human growth hormone glycosylation mutants

BIOGENERIX AG

O-linked glycosylation of peptides

ZYMEQUEST INC

Compositions and methods for prolonging survival of platelets

BAY DEV CORP SA

Method of using an antibody to the TN antigen for the inhibition of HIV infection

ROSIELLO KEITH

Methods of using an apparatus for prolonging survival of platelets using CMP-sialic acid, UDP-galactose or both

WANDALL HANS H

Method for early detection of cancer

GLYCOZM APS

UDP-galactose: β-N-acetyl-glucosamine β-1,4-galactosyl-transferase, β4Gal-T2

ROSIELLO KEITH M

Prolonging survival of platelets using CMP-sialic acid,UDP-galactose or both

GLYCOZYM USA INC

UDP-galactose:β-D-galactose-R 4-α-D-galactosyltransferase, α4gal-T1